Healthcare [ 5/11 ] | Drug Manufacturers—Specialty & Generic [ 36/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 11, 23 | -1.93 Increased by +94.61% | -0.63 Decreased by -206.35% |
| Feb 21, 23 | -1.31 Increased by +85.11% | -1.60 Increased by +18.13% |
| Nov 14, 22 | -1.20 Increased by +94.50% | -3.60 Increased by +66.67% |
| Sep 27, 22 | -9.80 Increased by +34.67% | -7.40 Decreased by -32.43% |
| May 16, 22 | -35.80 Decreased by -26.95% | -8.20 Decreased by -336.59% |
| Feb 14, 22 | -8.80 Increased by +37.14% | -11.60 Increased by +24.14% |
| Nov 15, 21 | -21.80 Decreased by -172.50% | -9.80 Decreased by -122.45% |
| Sep 27, 21 | -15.00 Decreased by -1.50 M% | -9.80 Decreased by -53.06% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 22.73 M Decreased by -6.06% | -5.84 M Increased by +95.83% | Decreased by -25.70% Increased by +95.57% |
| Dec 31, 22 | 26.28 M Increased by +13.64% | -10.39 M Increased by +10.03% | Decreased by -39.54% Increased by +20.83% |
| Sep 30, 22 | 27.66 M Increased by +26.30% | -4.24 M Increased by +84.79% | Decreased by -15.32% Increased by +87.95% |
| Jun 30, 22 | 27.45 M Increased by +16.89% | -38.06 M Decreased by -100.32% | Decreased by -138.65% Decreased by -71.38% |
| Mar 31, 22 | 24.20 M Increased by +79.49% | -140.25 M Decreased by -275.68% | Decreased by -579.57% Decreased by -109.31% |
| Dec 31, 21 | 23.13 M Increased by +52.67% | -11.55 M Decreased by -21.24% | Decreased by -49.94% Increased by +20.59% |
| Sep 30, 21 | 21.90 M Increased by +61.96% | -27.85 M Decreased by -451.20% | Decreased by -127.19% Decreased by -240.34% |
| Jun 30, 21 | 23.48 M Increased by +58.02% | -19.00 M Decreased by -490.22% | Decreased by -80.90% Decreased by -346.95% |
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.